This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Parcopa

Jazz Pharmaceuticals plc

Drug Names(s): carbidopa-levodopa orally disintegrating tablets

Description: Parcopa is an orally disintegrating form of levodopa, a precursor to dopamine, along with carbidopa, which prevents the metabolism of levodopa outside of the brain by the enzyme DDC.

Deal Structure: Schwarz licenses Parcopa's orally disintegrating technology from Cima labs, a division of Cephalon.

UCB and Schwarz
In July 2007, UCB acquired Schwarz Pharma.

Azur and UCB
In January 2009, Azur Pharma announced that it licensed the exclusive U.S. marketing rights for Parcopa from UCB. Financial terms were not disclosed.

Teva and Cephalon
In May 2011, Teva and Cephalon announced that their Boards of Directors unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The acquisition was closed in October 2011.

Jazz and Azur
In September 2011, Jazz Pharmaceuticals and Azur Pharma announced that the companies have agreed to combine in an all-stock transaction. The combined company would be named Jazz Pharmaceuticals plc. The combination of the companies was closed in January 2012.

Partners: Teva Pharmaceutical Industries Ltd. UCB SA


Parcopa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug